Authors
1
Assistant Professor, Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Greece.
2
Assistant Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Greece.
3
Associate Professor, Department of Biologic Chemistry, Athens University, Athens, Attiki, Greece.
4
Professor, Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Greece.
5
Director, Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Greece.
Abstract
Aim: This study compared the attenuatin effects of erythropoietin (Epo) and antioxidant drug U-74389G based on 2 preliminary studies. The provided results on blood platelet counts were co-evaluated in a hypoxia reoxygenation protocol of an animal model.
Materials and methods: Blood platelet counts were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G.
Results: The first preliminary study recommended a non-significant attenuating effect of Epo (p-value=0.9725). The second preliminary study also recommended a more powerful attenuating effect of U-74389G (p-value=0.0857). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has at least 37-fold more attenuating action than Epo (p-value=0.0000).
Conclusions: The hematologist must be informed about the effective attenuating potencies of U-74389G in related coagulant and clotting situations.
Keywords
)